R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Abstract The use of non‐pegylated liposomal doxorubicin (Myocet®) in diffuse large B‐cell lymphoma (DLBCL) has been investigated in retrospective and single‐arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥5...

Full description

Bibliographic Details
Main Authors: Juan‐Manuel Sancho, Rubén Fernández‐Alvarez, Francisco Gual‐Capllonch, Esther González‐García, Carlos Grande, Norma Gutiérrez, María‐Jesús Peñarrubia, Ana Batlle‐López, Eva González‐Barca, José‐María Guinea, Eva Gimeno, Francisco‐Javier Peñalver, Miguel Fuertes, Mariana Bastos, José‐Ángel Hernández‐Rivas, José‐María Moraleda, Olga García, Marc Sorigué, Alejandro Martin
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Cancer Medicine
Subjects:
cardiotoxicity
diffuse large B‐cell lymphoma
liposomal doxorubicin
N‐terminal pro‐B‐type natriuretic peptide
troponin
Online Access:https://doi.org/10.1002/cam4.3730

Internet

https://doi.org/10.1002/cam4.3730

Similar Items